Publications by authors named "April A N Rose"

19Publications

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.

Authors:
Aljosja Rogiers Ines Pires da Silva Chiara Tentori Carlo Alberto Tondini Joseph M Grimes Megan H Trager Sharon Nahm Leyre Zubiri Michael Manos Peter Bowling Arielle Elkrief Neha Papneja Maria Grazia Vitale April A N Rose Jessica S W Borgers Severine Roy Joanna Mangana Thiago Pimentel Muniz Tim Cooksley Jeremy Lupu Alon Vaisman Samuel D Saibil Marcus O Butler Alexander M Menzies Matteo S Carlino Michael Erdmann Carola Berking Lisa Zimmer Dirk Schadendorf Laura Pala Paola Queirolo Christian Posch Axel Hauschild Reinhard Dummer John Haanen Christian U Blank Caroline Robert Ryan J Sullivan Paolo Antonio Ascierto Wilson H Miller F Stephen Hodi Karijn P M Suijkerbuijk Kerry L Reynolds Osama E Rahma Paul C Lorigan Richard D Carvajal Serigne Lo Mario Mandala Georgina V Long

J Immunother Cancer 2021 01;9(1)

Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia

View Article and Find Full Text PDF
January 2021

Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement Initiative.

Authors:
Michelle B Nadler April A N Rose Rebecca Prince Lawson Eng Anthony Lott Robert C Grant Jennifer M Jones Katherine Enright

JCO Oncol Pract 2020 Dec 8:OP2000432. Epub 2020 Dec 8.

University of Toronto, ON, Canada.

View Article and Find Full Text PDF
December 2020

BRAF Mutation Class and Clinical Outcomes-Letter.

Authors:
Matthew Dankner April A N Rose

Clin Cancer Res 2019 05;25(10):3188

Faculty of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
May 2019

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Authors:
Matthew Dankner Mathieu Lajoie Dan Moldoveanu Tan-Trieu Nguyen Paul Savage Shivshankari Rajkumar Xiu Huang Maria Lvova Alexei Protopopov Dana Vuzman David Hogg Morag Park Marie-Christine Guiot Kevin Petrecca Catalin Mihalcioiu Ian R Watson Peter M Siegel April A N Rose

Clin Cancer Res 2018 12 14;24(24):6483-6494. Epub 2018 Jun 14.

Division of Medical Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

View Article and Find Full Text PDF
December 2018

Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.

Authors:
Matthew Dankner April A N Rose

Br J Cancer 2018 05 22;118(9):1276-1277. Epub 2018 Mar 22.

Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, ON, Canada.

View Article and Find Full Text PDF
May 2018

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:
Matthew Dankner April A N Rose Shivshankari Rajkumar Peter M Siegel Ian R Watson

Oncogene 2018 06 15;37(24):3183-3199. Epub 2018 Mar 15.

Goodman Cancer Research Centre, McGill University, Montreal, QC, Canada.

View Article and Find Full Text PDF
June 2018

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Authors:
April A N Rose Marco Biondini Rafael Curiel Peter M Siegel

Pharmacol Ther 2017 Nov 22;179:127-141. Epub 2017 May 22.

Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada; Department of Medicine, McGill University, Montréal, Québec, Canada; Department of Biochemistry, McGill University, Montréal, Québec, Canada; Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada; Department of Oncology, McGill University, Montréal, Québec, Canada. Electronic address:

View Article and Find Full Text PDF
November 2017

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Authors:
April A N Rose Matthew G Annis Dennie T Frederick Marco Biondini Zhifeng Dong Lawrence Kwong Lynda Chin Tibor Keler Thomas Hawthorne Ian R Watson Keith T Flaherty Peter M Siegel

Clin Cancer Res 2016 Dec 11;22(24):6088-6098. Epub 2016 Aug 11.

Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada.

View Article and Find Full Text PDF
December 2016

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.

Authors:
Sébastien Tabariès Véronique Ouellet Brian E Hsu Matthew G Annis April A N Rose Liliane Meunier Euridice Carmona Christine E Tam Anne-Marie Mes-Masson Peter M Siegel

Breast Cancer Res 2015 Mar 27;17:45. Epub 2015 Mar 27.

Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Room 513, Montréal, QC, H3A 1A3, Canada.

View Article and Find Full Text PDF
March 2015

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Authors:
Johanna Bendell Mansoor Saleh April A N Rose Peter M Siegel Lowell Hart Surendra Sirpal Suzanne Jones Jennifer Green Elizabeth Crowley Ronit Simantov Tibor Keler Thomas Davis Linda Vahdat

J Clin Oncol 2014 Nov 29;32(32):3619-25. Epub 2014 Sep 29.

Johanna Bendell and Suzanne Jones, Sarah Cannon Research Institute, Nashville, TN; Mansoor Saleh, Georgia Cancer Specialists, Atlanta, GA; April A.N. Rose and Peter M. Siegel, Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada; Lowell Hart, Florida Cancer Specialists, Fort Myers; Surendra Sirpal, Hematology Oncology Associates, Lake Worth, FL; Jennifer Green, Elizabeth Crowley, Ronit Simantov, Tibor Keler, and Thomas Davis, Celldex Therapeutics; and Linda Vahdat, Weill Cornell Medical College, New York, NY.

View Article and Find Full Text PDF
November 2014

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis.

Authors:
April A N Rose Christine Elser Marguerite Ennis Pamela J Goodwin

Breast Cancer Res Treat 2013 Oct 9;141(3):331-9. Epub 2013 Oct 9.

Faculty of Medicine, McGill University, McIntyre Medical Building, 3655 Sir William Osler, Montreal, QC, H3G 1Y6, Canada.

View Article and Find Full Text PDF
October 2013

ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:
April A N Rose Matthew G Annis Zhifeng Dong Francois Pepin Michael Hallett Morag Park Peter M Siegel

PLoS One 2010 Aug 10;5(8):e12093. Epub 2010 Aug 10.

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.

View Article and Find Full Text PDF
August 2010

Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.

Authors:
Amandine Bemmo Christel Dias April A N Rose Caterina Russo Peter Siegel Jacek Majewski

PLoS One 2010 Aug 6;5(8):e11981. Epub 2010 Aug 6.

Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

View Article and Find Full Text PDF
August 2010

Overexpression of galectin-7, a myoepithelial cell marker, enhances spontaneous metastasis of breast cancer cells.

Authors:
Mélanie Demers April A N Rose Andrée-Anne Grosset Katherine Biron-Pain Louis Gaboury Peter M Siegel Yves St-Pierre

Am J Pathol 2010 Jun 9;176(6):3023-31. Epub 2010 Apr 9.

Institut national de la recherche scientifique-Institut Armand-Frappier, Laval, Québec, Canada, H7V 1B7.

View Article and Find Full Text PDF
June 2010

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Authors:
April A N Rose Andrée-Anne Grosset Zhifeng Dong Caterina Russo Patricia A Macdonald Nicholas R Bertos Yves St-Pierre Ronit Simantov Michael Hallett Morag Park Louis Gaboury Peter M Siegel

Clin Cancer Res 2010 Apr 9;16(7):2147-56. Epub 2010 Mar 9.

Department of Medicine, Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West Montréal, Québec, Canada, H3A 1A3.

View Article and Find Full Text PDF
April 2010

Emerging therapeutic targets in breast cancer bone metastasis.

Authors:
April A N Rose Peter M Siegel

Future Oncol 2010 Jan;6(1):55-74

Department of Medicine, Goodman Cancer Centre, McGill University, QC H3A 1A3, Canada.

View Article and Find Full Text PDF
January 2010

Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?

Authors:
April A N Rose Peter M Siegel

Breast Cancer Res 2007 ;9(6):403

View Article and Find Full Text PDF
March 2008

Osteoactivin promotes breast cancer metastasis to bone.

Authors:
April A N Rose François Pepin Caterina Russo Jad E Abou Khalil Michael Hallett Peter M Siegel

Mol Cancer Res 2007 Oct;5(10):1001-14

Department of Medicine, McGill University, Montreal, Quebec, Canada.

View Article and Find Full Text PDF
October 2007

Breast cancer-derived factors facilitate osteolytic bone metastasis.

Authors:
April A N Rose Peter M Siegel

Bull Cancer 2006 Sep;93(9):931-43

Department of Medicine, McGill University, 740 Dr. Penfield Avenue, Room 2201, Montreal, Quebec, Canada, H3A 1A4.

View Article and Find Full Text PDF
September 2006